ImmunityBio Begins European ANKTIVA Treatment Rollout
Culver City, California, United States; Germany and Austria, November 4, 2026 ImmunityBio, Inc. has announced that the first patients...
bladder cancer
Advertisement
Natera Highlights Signatera’s Potential in Bladder Cancer at ESMO 2026
AUSTIN, Texas, United States — October 27, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision...
Pfizer to Present 45 Oncology Abstracts at ESMO 2026
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
AstraZeneca Gains US Priority Review for IMFINZI in MIBC
WILMINGTON, Del. — September 25, 2026 AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted and...
Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Advertisements
Olatec Therapeutics Adds Parkinson’s Disease Experts
New York, New York, U.S., September 15, 2026 Olatec Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for inflammatory...
Astellas PADCEV and Keytruda Gain Positive CHMP Opinion
Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...
Insilico Doses First Patient in AI-Driven Phase 3 IPF Trial
New York, New York, September 10, 2026 Insilico Medicine has announced that the first patient has been dosed in...
IDEAYA and Servier Launch Phase 3 Uveal Melanoma Trial
South San Francisco, California and Paris, France, September 9, 2026 IDEAYA Biosciences and Servier have announced that the first...
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Advertisement
